- Home
- CEG vs MRNA Comparison
CEG vs MRNA Comparison
Compare CEG & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEG
- MRNA
- Stock Information
- Founded
- CEG 1999
- MRNA 2010
- Country
- CEG United States
- MRNA United States
- Employees
- CEG N/A
- MRNA N/A
- Industry
- CEG Electric Utilities: Central
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CEG Utilities
- MRNA Health Care
- Exchange
- CEG Nasdaq
- MRNA Nasdaq
- Market Cap
- CEG 87.4B
- MRNA 34.6B
- IPO Year
- CEG N/A
- MRNA 2018
- Fundamental
- Price
- CEG $271.20
- MRNA $54.82
- Analyst Decision
- CEG Buy
- MRNA Hold
- Analyst Count
- CEG 13
- MRNA 16
- Target Price
- CEG $280.08
- MRNA $95.93
- AVG Volume (30 Days)
- CEG 4.5M
- MRNA 5.0M
- Earning Date
- CEG 11-04-2024
- MRNA 11-07-2024
- Dividend Yield
- CEG 0.52%
- MRNA N/A
- EPS Growth
- CEG 218.04
- MRNA N/A
- EPS
- CEG 7.49
- MRNA N/A
- Revenue
- CEG $23,544,000,000.00
- MRNA $5,050,000,000.00
- Revenue This Year
- CEG N/A
- MRNA N/A
- Revenue Next Year
- CEG $2.41
- MRNA $5.29
- P/E Ratio
- CEG $36.19
- MRNA N/A
- Revenue Growth
- CEG N/A
- MRNA N/A
- 52 Week Low
- CEG $109.44
- MRNA $54.82
- 52 Week High
- CEG $288.75
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- CEG 61.62
- MRNA 25.28
- Support Level
- CEG $262.34
- MRNA $55.70
- Resistance Level
- CEG $272.82
- MRNA $59.73
- Average True Range (ATR)
- CEG 11.84
- MRNA 2.17
- MACD
- CEG -2.08
- MRNA 0.29
- Stochastic Oscillator
- CEG 55.79
- MRNA 0.00
About CEG Constellation Energy Corporation
Constellation Energy Corp offers energy solutions. It provides clean energy and sustainable solutions to homes, businesses, the public sector, community aggregations, and a range of wholesale customers (such as municipalities, cooperatives, and other strategics). The company offers comprehensive energy solutions and a variety of pricing options for electric, natural gas, and renewable energy products for companies of any size.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.